Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Mallinckrodt
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Last Updated: March 22, 2023

Investigational Drug Information for OTO-104


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug OTO-104?

OTO-104 is an investigational drug.

There have been 27 clinical trials for OTO-104. The most recent clinical trial was a Phase 3 trial, which was initiated on January 13th 2021.

The most common disease conditions in clinical trials are Meniere Disease, Otitis, and Otitis Media. The leading clinical trial sponsors are Otonomy, Inc., University of St Andrews, and Stellah Mpagama.

There are eight hundred and thirty-two US patents protecting this investigational drug and forty-two international patents.

Recent Clinical Trials for OTO-104
TitleSponsorPhase
A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary TuberculosisRadboud University Medical CenterPhase 3
A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary TuberculosisUniversity of St AndrewsPhase 3
A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary TuberculosisStellah MpagamaPhase 3

See all OTO-104 clinical trials

Clinical Trial Summary for OTO-104

Top disease conditions for OTO-104
Top clinical trial sponsors for OTO-104

See all OTO-104 clinical trials

US Patents for OTO-104

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
OTO-104 See Plans and Pricing IBAT inhibitors for the treatment of liver diseases Albireo AB (Gothenburg, SE) See Plans and Pricing
OTO-104 See Plans and Pricing Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH) See Plans and Pricing
OTO-104 See Plans and Pricing Salts of an epidermal growth factor receptor kinase inhibitor Celgene CAR LLC (Pembroke, BM) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Mallinckrodt
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.